Abstract
The combined use of hypoglycemic drugs Glucovance (glyburide + metformin) and rosiglitazone has been evaluated in nonpregnant patients with type 2 diabetes mellitus. However, the role of the placenta in the biodisposition of a combination of oral hypoglycemic drugs during pregnancy remains unclear. Previous reports from our laboratory demonstrated that multiple drugs could compete for efflux by P-glycoprotein (P-gp). Therefore, co-administration of hypoglycemic drugs which are substrates of placental efflux transporters could introduce competition for a single efflux transporter thus increasing their transfer to the fetal circulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
